Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil in Parkinson's disease
2021-003879-34Phase 2Active
- Sponsor
- Klinikum rechts der Isar
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fasudil in Parkinson's disease (PD), sponsored by Klinikum rechts der Isar. Primary endpoint: Combined occurrence of intolerance and treatment-related serious adverse events. Started Aug 2022; status: active.
02
Drugs
fasudil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2021-003879-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003879-34.